Dermatology

>

Latest News

Arcutissubmits roflumilast 0.15% sNDAfor AD in children 6 years and up | Image Credit: © lial88 - © lial88 - stock.adobe.com.
Arcutis submits roflumilast 0.15% sNDA for AD in children 6 years and up

September 21st 2023

Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older.

Roflumilast cream 0.05% safe, effective for children aged 2 to 5 years with atopic dermatitis | Image Credit: © Марина Терехова - © Марина Терехова - stock.adobe.com.
Roflumilast cream 0.05% safe, effective for children aged 2 to 5 years with atopic dermatitis

September 20th 2023

Alopecia in adolescents | Image Credit: Author provided
Alopecia in adolescents

September 15th 2023

Bernard A. Cohen, MD, professor of pediatrics and dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland
Discussing VP-102 to treat molluscum contagiosum in patients 2 years and up

September 5th 2023

Masters of pediatric dermatology course offered to healthcare providers | Image Credit: © Paweł Kacperek - © Paweł Kacperek - stock.adobe.com.
Masters of pediatric dermatology course offered to healthcare providers

July 25th 2023

Video Interviews
Podcasts
stock image of a hemangioma

More News

© 2023 MJH Life Sciences

All rights reserved.